Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.8K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.8K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

760
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
760
Inhaled Medications01:23

Inhaled Medications

769
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
769
Pulmonary Ventilation: Inhalation01:24

Pulmonary Ventilation: Inhalation

7.8K
Pulmonary ventilation is a vital process that ensures the exchange of oxygen and carbon dioxide in the lungs. It refers to the movement of air into and out of the lungs, enabling the body to obtain oxygen and remove waste carbon dioxide. In this article, we will explore the intricacies of pulmonary ventilation, including its underlying principles, mechanisms, and the interplay of pressures within the respiratory system.
Boyle's law becomes particularly pertinent when examining respiratory...
7.8K
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

1.1K
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
1.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osmotic Remodeling of Extracellular Vesicles for Precision Nanomedicine.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Phenotyping of Obstructive Sleep Apnea Syndrome and Association with Cognitive Impairment, a Real-Life Study.

Biomedicines·2026
Same author

Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders.

Biomedicines·2026
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

Benign Bronchial Tumours: A Rare Case of Endobronchial Fibroma With Hilar-Mediastinal Lymphadenopathy.

Case reports in pulmonology·2026
Same author

Impact of Single-Inhaler Triple Therapy FF/UMEC/VI on Disease Stability in COPD: A Real-World 12-Month Analysis.

Pulmonary therapy·2026

Related Experiment Video

Updated: Jan 24, 2026

Whole-Body Nanoparticle Aerosol Inhalation Exposures
10:11

Whole-Body Nanoparticle Aerosol Inhalation Exposures

Published on: May 7, 2013

16.3K

Single Inhaler LABA/LAMA for COPD.

Mario Malerba1,2, Valentina Foci1,2, Filippo Patrucco1,2

  • 1Respiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, Italy.

Frontiers in Pharmacology
|May 21, 2019
PubMed
Summary
This summary is machine-generated.

Long-acting muscarinic antagonist and long-acting beta agonist (LAMA/LABA) inhalers are key for managing stable chronic obstructive pulmonary disease (COPD). This review critically examines their pharmacology and clinical use, discussing current debates and future directions for COPD treatment.

Keywords:
LABALAMAchronic obstructive pulmonary disease (COPD)fixed dose combination (FDC)maintenance treatment

More Related Videos

Immunization of Alpacas Lama pacos with Protein Antigens and Production of Antigen-specific Single Domain Antibodies
05:27

Immunization of Alpacas Lama pacos with Protein Antigens and Production of Antigen-specific Single Domain Antibodies

Published on: January 26, 2019

24.6K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

7.6K

Related Experiment Videos

Last Updated: Jan 24, 2026

Whole-Body Nanoparticle Aerosol Inhalation Exposures
10:11

Whole-Body Nanoparticle Aerosol Inhalation Exposures

Published on: May 7, 2013

16.3K
Immunization of Alpacas Lama pacos with Protein Antigens and Production of Antigen-specific Single Domain Antibodies
05:27

Immunization of Alpacas Lama pacos with Protein Antigens and Production of Antigen-specific Single Domain Antibodies

Published on: January 26, 2019

24.6K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

7.6K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Medicine

Background:

  • Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition causing airflow limitation.
  • Current COPD management guidelines recommend dual bronchodilation using long-acting muscarinic antagonists (LAMAs) and long-acting beta agonists (LABAs).
  • Fixed-dose combinations of LAMA/LABA inhalers are increasingly utilized for stable COPD maintenance therapy.

Purpose of the Study:

  • To critically review the pharmacological and clinical aspects of LAMA/LABA single inhalers in stable COPD.
  • To highlight key areas of debate and future prospects in LAMA/LABA combination therapy for COPD.
  • To provide a comprehensive overview for healthcare professionals managing COPD patients.

Main Methods:

  • Literature review of pharmacological data and clinical trial results.
  • Critical analysis of existing evidence on LAMA/LABA fixed-dose combinations.
  • Synthesis of information on debated topics and future research directions.

Main Results:

  • LAMA/LABA combinations offer significant benefits in improving symptoms, quality of life, and reducing exacerbations in COPD.
  • Various fixed-dose LAMA/LABA inhalers are available, supported by extensive clinical trial data.
  • Ongoing research focuses on optimizing delivery devices, understanding long-term effects, and individualizing treatment.

Conclusions:

  • LAMA/LABA single inhalers represent a cornerstone in the maintenance treatment of stable COPD.
  • Further research is needed to address specific patient populations and refine treatment strategies.
  • The field is evolving, with potential for novel combinations and improved therapeutic outcomes in COPD management.